EFF statement on Johnson & Johnson vaccine clinical trial
2 March 2021
The EFF notes with concern the misleading of the nation by the Cyril Ramaphosa's administration and lack of transparency of Minister Zwelini Mkhize. Minister Zwelini Mkhize failed to divulge necessary information on the Johnson & Johnson vaccine trial being presented and carried through as an actual vaccination process whilst it is undergoing phase 3B of vaccine trials for Covid-19 in South Africa.
On the 10. of February 2021, the EFF in the Portfolio Committee on Health in parliament raised a concern to the Minister of Health and the National Department of Health on why the research presented to the committee was not inclusive of placebo details pertaining to the Johnson & Johnson vaccine. The Minister of Health was presented with an opportunity to assert that part and parcel of the void of placebo details was the case because the Johnson &Johnson vaccine was still undergoing trial. Instead, Minister Zwelini Mkhize defended the lack of vital evidence and furthermore failed to clarify to the Portfolio Committee on Health that the Johnson &Johnson vaccine was still undergoing phase 3B of trials in the country.
The request for placebo details is primarily important information to note in the comparison of various vaccine trials for Covid-19 that other manufacturers were able to provide besides Johnson & Johnson. Placebos are a vital part of justifying the safety and effectiveness of medicinal interventions in clinical studies and provide researchers data for comparison in regards to devising new therapies.
It is shameful that the Minister of Health, Zwelini Mkhize, subverted the ethical process of ensuring that the nation and thus participants in the Johnson & Johnson vaccine trial are fully made aware that they are participating in a trial and not necessarily the actual rollout of the vaccine as communicated on public platforms as "Phase 1 of the Vaccine Rollout Strategy". It is further shameful and criminal that the Minister of Health abused the South African Health Products Regulatory Authority processes by presenting a vaccine trial as a rollout when it was only approved for research purposes.